The conference is the world’s largest meeting dedicated to lung
cancer and other thoracic malignancies
Novocure (NASDAQ: NVCR) announced today five data presentations
at the International Associations for the Study of Lung Cancer
(IASLC) 18th World Conference on Lung Cancer, October 15 to October
18 in Yokohama, Japan.
“We look forward to having our research on Tumor Treating Fields
(TTFields) presented at the world’s largest meeting dedicated to
lung cancer and other thoracic malignancies,” said Dr. Eilon
Kirson, Novocure’s Chief Science Officer and Head of Research and
Development. “Lung cancer is the most common cause of cancer death
worldwide. TTFields shows promise in multiple solid tumor types,
including some of the most aggressive forms of cancer. We are
committed to researching TTFields as a treatment for multiple solid
tumor types and sharing our findings with the scientific
community.”
The following posters will be presented at the IASLC World
Conference on Lung Cancer:
Advanced non-small cell lung cancer
(P3.01-088d) TTFields Combined with PD-1 Inhibitors or Docetaxel
for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) (ID
7563): Phase 3 LUNAR Study. U. Weinberg, O. Farber, M. Giladi, Z.
Bomzon, E. Kirson. 9:30 a.m. to 4 p.m. JST October 18. (Exhibit
Hall, Hall B + C)
(P3.01-088e) TTFields Delivery to the Brain: An Overview of
Computational Studies and Implications When Treating Brain
Metastases (ID 8773). S. Levi, Z. Bomzon, A. Naveh, E. Kirson, U.
Weinberg. 9:30 a.m. to 4 p.m. JST October 18. (Exhibit Hall, Hall B
+ C)
Clinical design, statistics and clinical trials
(P3.04-013b) TTFields and Radiosurgery for 1-10 Brain Metastases
from NSCLC: The Phase 3 METIS Study (ID 7562). M. Mehta, V. Gondi,
M. Ahluwalia, P. Brown. 9:30 a.m. to 4 p.m. JST October 18.
(Exhibit Hall, Hall B + C)
Immunology and immunotherapy
(P3.07-013c) Computational Simulations for Investigating
Electric Field Distributions When Delivering Tumor Treating Fields
(TTFields) to the Lungs (ID 8776). H. Hershkovich, O. Yesharim, N.
Urman, A. Naveh, U. Weinberg, E. Kirson, Z. Bomzon U. Weinberg.
9:30 a.m. to 4 p.m. JST October 18. (Exhibit Hall, Hall B + C)
(P3.07-013d) Tumor Treating Fields Induce Immunogenic Cell Death
and Enhance Antitumor Effects of Anti-PD1 in NSCLC In-Vivo Models
(ID 8952). T. Voloshin, O. Yitzhaki, M. Giladi, N. Kaynan, A.
Shteingauz, M. Munster, R. Blat, Y. Porat, R. Schneiderman, E.
Zeevi, S. Cahal, A. Itzhaki, E. Kirson, U. Weinberg, Y. Palti. 9:30
a.m. to 4 p.m. JST October 18. (Exhibit Hall, Hall B + C)
About Novocure
Novocure is an oncology company developing a profoundly
different cancer treatment utilizing a proprietary therapy called
TTFields, the use of electric fields tuned to specific frequencies
to disrupt solid tumor cancer cell division. Novocure’s
commercialized product, Optune, is approved for the treatment of
adult patients with glioblastoma. Novocure has ongoing or completed
clinical trials investigating TTFields in brain metastases,
non-small cell lung cancer, pancreatic cancer, ovarian cancer and
mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in
Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City.
Additionally, the company has offices in Germany, Switzerland,
Japan and Israel. For additional information about the company,
please visit www.novocure.com or follow us at
www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as “anticipate,” “estimate,” “expect,” “project,” “intend,”
“plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2017, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171016005152/en/
Media and Investor Contact:NovocureAshley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Sep 2023 to Sep 2024